Blog

Merck, riding clinical success, eyes cancer immunotherapy lead – BioPharma Dive


Miami Herald

Merck, riding clinical success, eyes cancer immunotherapy lead
BioPharma Dive
Merck & Co.'s flagship cancer drug Keytruda surpassed diabetes medicines Januvia and Janumet as the pharma's top-selling therapeutic franchise in the first quarter, underscoring the rapid sales growth of the immunotherapy over the past year. Sales of
Merck lifts earnings forecast after currency boostFinancial Times



all 101 news articles »

2018-05-01 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.